End-to-end cell therapy automation

Patent metadata

Field	Value
Publication number	US-11447745-B2
Application number	US-201816119618-A
Country	US
Kind code	B2
Filing date	Aug 31, 2018
Priority date	Sep 1, 2017
Publication date	Sep 20, 2022
Grant date	Sep 20, 2022

Abstract

The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

First claim

The invention claimed is:

1. A method for automated production of a genetically modified T cell culture, the method comprising:
(a) activating a T cell culture with an activation reagent selected from an antibody and a dendritic cell to produce an activated T cell culture;
(b) transducing within a cell culture chamber the activated T cell culture with a viral vector encoding an ectodomain, a transmembrane domain, and an endodomain, to introduce the viral vector into the activated T cell culture and produce a transduced T cell culture;
(c) expanding within the cell culture chamber the transduced T cell culture;
(d) concentrating the expanded T cell culture of (c); and
(e) harvesting the concentrated T cell culture of (d) to produce a genetically modified T cell culture,
further comprising washing either or both the expanded T cell culture and the concentrated T cell culture,
wherein (a) through (e) are performed within a fully enclosed cell engineering system, and the cell culture chamber has a fixed area, and
wherein expansion of the transduced T cell culture in (c) produces at least 20% more genetically modified T cells than expansion utilizing manual cell culture with a flexible, gas permeable bag.

2. The method of claim 1 , wherein the process is a self-adjusting process and includes:
(a) monitoring with one or more of a temperature sensor, a pH sensor, a glucose sensor, an oxygen sensor, a carbon dioxide sensor, and an optical density sensor; and
(b) adjusting one or more of a temperature, a pH level, a glucose level, an oxygen level, a carbon dioxide level, and an optical density of the transduced T cell culture, based on the monitoring.

3. The method of claim 1 , wherein the method produces at least about 100 million viable genetically modified T cells.

4. The method of claim 1 , wherein T cell culture is a chimeric antigen receptor T (CAR T) cell culture.

5. The method of claim 1 , wherein an oxygen level of the transduced T cell culture is optimized for the T cell culture.

6. The method of claim 1 , wherein the cell engineering system recirculates cell culture media through an oxygenation component during one or more of steps (a) to (e), and wherein the cell engineering system recirculates nutrients, waste, released cytokines, and/or dissolved gasses during steps (a) to (e).

7. The method of claim 1 , wherein the activating is within the cell culture chamber.

8. A method for automated production of a chimeric antigen receptor T (CAR T) cell culture, the method comprising:
(a) activating a T cell culture with an antibody to produce an activated T cell culture, wherein the antibody and activating conditions promote the phenotype of the genetically modified T cell culture;
(b) transducing within a cell culture chamber the activated T cell culture with a viral vector encoding a chimeric antigen receptor having an ectodomain, a transmembrane domain, and an endodomain, to produce a transduced CAR T cell culture;
(c) expanding within the cell culture chamber the transduced CAR T cell culture;
(d) concentrating the expanded CAR T cell culture of (c); and
(e) harvesting the concentrated CAR T cell culture of (d) to produce a genetically modified CAR T cell culture,
wherein (a) through (e) are performed within a fully enclosed, automated cell engineering system, and the cell culture chamber has a fixed area; and
wherein expansion of the transduced CAR T cell culture of (c) produces at least 20% more genetically modified CAR T cells than expansion utilizing manual cell culture with a flexible, gas permeable bag.

9. The method of claim 8 , wherein each of (a) through (e) are performed with T cell cultures having an optimized cell density (cells/mL) and an optimized cell confluency (cells/cm 2 ).

10. The method of claim 8 , wherein the activating is within the cell culture chamber.

11. A method for automated production of a genetically modified T cell culture, the method comprising:
(a) activating a T cell culture with an activation reagent selected from an antibody and a dendritic cell to produce an activated T cell culture;
(b) transducing within a cell culture chamber the activated T cell culture with a viral vector encoding an ectodomain, a transmembrane domain and an endodomain, to produce a transduced T cell culture;
(c) expanding within the cell culture chamber the transduced T cell culture;
(d) concentrating the expanded T cell culture of (c); and
(e) harvesting the concentrated T cell culture of (d) to produce a genetically modified T cell culture,
wherein (a) through (e) are performed within a fully enclosed, automated cell engineering system, and the cell culture chamber has a fixed area; and
wherein expansion of the transduced T cell culture in (c) produces at least 20% more genetically modified T cells than expansion utilizing manual cell culture with a flexible, gas permeable bag.

12. The method of claim 11 , wherein the activation reagent comprises an antibody.

13. The method of claim 12 , wherein the antibody is immobilized on a surface.

14. The method of claim 13 , wherein the surface is a surface of a bead.

15. The method of claim 12 , wherein the antibody is a soluble antibody.

16. The method of claim 12 , wherein the antibody comprises at least one of an anti-CD3 antibody, an anti-CD28 antibody and an anti-CD2 antibody.

17. The method of claim 11 , wherein the method produces at least about 100 million viable genetically modified T cells.

18. The method of claim 11 , wherein T cell culture is a chimeric antigen receptor T (CAR T) cell culture.

19. The method of claim 18 , wherein the vector encodes a chimeric antigen receptor.

20. The method of claim 11 , wherein the T cell culture comprises peripheral blood mononuclear cells and/or purified T cells.

21. The method of claim 11 , wherein the cell culture comprises at least one accessory cell.

22. The method of claim 21 , wherein the accessory cell comprises a monocyte or a monocyte-derived cell.

23. The method of claim 22 , wherein the accessory cell comprises antigens for a T cell receptor selected from CD28, CD40, CD2, CD40L ICOS, and combinations thereof.

24. The method of claim 11 , wherein the viral vector is a lentiviral vector or a retrovirus.

25. The method of claim 11 , wherein the transducing comprises mixing the viral vector in cell culture media and delivering the viral vector in the media uniformly to the activated T cell culture.

26. The method of claim 11 , wherein the expanding comprises feeding, washing, monitoring, and selecting of the transduced T cell culture.

27. The method of claim 11 , wherein an oxygen level of the transduced T cell culture is optimized for the T cell culture.

28. The method of claim 11 , wherein the cell engineering system recirculates cell culture media through an oxygenation component during one or more of steps (a) to (e).

29. The method of claim 11 , wherein the cell engineering system recirculates nutrients, waste, released cytokines, and/or dissolved gasses.

30. The method of claim 11 , wherein a carbon dioxide level provided by the cell engineering system decreases during step (c).

31. The method of claim 11 , wherein the cell engineering system is capable of performing several rounds of feeding, washing, monitoring, and selecting of the transduced T ce

Assignees

• Lonza Walkersville Inc
• Lonza Cologne Gmbh
• Octane Biotech Inc

Inventors

• Shi Yaling
• Mcafee Erika
• Bandapalle Samatha
• Siehoff Ann
• Gleissner Timo
• O'Connor Joseph
• Abraham Eytan
• Purpura Kelly
• Trainor Nuala
• Smith Timothy

Classifications

• C12N2800/107

  for mammalian · CPC title

• C12N2510/00

  Genetically modified cells · CPC title

• C12N2501/515

  CD3, T-cell receptor complex · CPC title

• C12N2501/51

  B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand) · CPC title

• C07K2319/03

  containing a transmembrane segment · CPC title